The endocannabinoid system in IBS and cannabis as therapy

Introduction and clinical context

The study The endocannabinoid system in IBS and cannabis as therapy (PubMed · 2020) is part of the scientific research on the use of cannabinoids in irritable bowel syndrome.

In irritable bowel syndrome (IBS), a functional disorder of the gastrointestinal tract, researchers study the role of the endocannabinoid system in motility, visceral pain and intestinal sensitivity. Reviews and cohort studies explore the potential of cannabis in managing symptoms, but the evidence is still limited and heterogeneous. Gastroenterological follow-up is essential.

Understanding what science shows about the use of cannabinoids in irritable bowel syndrome helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. Review of the role of the endocannabinoid system in irritable bowel syndrome and the potential of cannabis. As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

In IBS, the endocannabinoid system regulates motility, secretion and, above all, visceral sensitivity and the gut-brain axis — a target of interest for relieving abdominal pain and discomfort, with CBD and THC acting on the CB1/CB2 receptors of the digestive tract. Regarding safety, drowsiness and dizziness are observed, with attention to interactions and to the risk of tolerance with prolonged use. As the evidence is still limited, use should be cautious, individualized and monitored by the gastroenterologist, without replacing established dietary and clinical measures.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PubMed · 2020). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis treat IBS?

The research explores symptom management, but the evidence is limited; gastroenterological follow-up is essential.

What is the role of the endocannabinoid system in the gut?

It takes part in motility, visceral pain and intestinal sensitivity.